Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The approval could unlock a big new market opportunity for Wegovy, as MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people worldwide and has been billed as pharma's next big growth area, with some analysts predicting a market potentially worth tens of billions of dollars a year
Made for GLP-1 supportive nutrition plans
The hepatic enzyme inhibition may cause an additional increase in potency and a prolonged metabolic half-life (prolonged metabolic half-life for all ways of drug administration)
Saxenda (liraglutide) [prescribing information]
With a list price around $1,086 per 28-day supply, it was even more expensive than Wegovy on a per-dose basis
US$ 22.82
US$ 29.79
US$ 28.74
US$ 28.72
US$ 22.55
US$ 26.93
US$ 21.21
